Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
Phase 3
Completed
- Conditions
- Hepatitis C
- Registration Number
- NCT00239252
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Hepatitis C patients (high titer, genotype1)
Exclusion Criteria
- Patients with autoimmune disorder
- Patients with negative HBs antigen
- Patients with hepatic cirrhosis, hepatic failure and hepatic cancer
- Patients with depression or psychoneurotic disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which interferon alfacon-1 and ribavirin synergistically inhibit HCV replication in genotype 1a patients?
How does the efficacy of interferon alfacon-1 monotherapy compare to combination therapy with ribavirin in HCV-infected individuals with compensated cirrhosis?
Which biomarkers correlate with sustained virological response in NCT00239252's interferon alfacon-1 and ribavirin treatment groups for HCV genotype 2/3?
What are the management strategies for ribavirin-induced hemolytic anemia in combination therapy with interferon alfacon-1 for chronic hepatitis C?
How do newer direct-acting antivirals compare to the interferon alfacon-1 and ribavirin regimen in HCV treatment outcomes?